Neuphoria Therapeutics Inc. (NEUP) — 10-Q Filings
All 10-Q filings from Neuphoria Therapeutics Inc.. Browse 4 Quarterly Report reports with AI-powered summaries and risk analysis.
10-Q Filings (4)
-
Neuphoria's Net Loss Skyrockets to $9.9M Amid R&D Surge
— Nov 14, 2025 Risk: high
Neuphoria Therapeutics Inc. (NEUP) reported a significant increase in net loss for the three months ended September 30, 2025, reaching $9.91 million, a substant -
Neuphoria Therapeutics Inc. Files Q3 2025 10-Q
— May 20, 2025 Risk: medium
Neuphoria Therapeutics Inc. filed its 10-Q for the period ending March 31, 2025. The company, formerly Bionomics Limited, is in the pharmaceutical preparations -
Neuphoria Therapeutics Files 10-Q for Q2 2024
— Feb 14, 2025 Risk: medium
Neuphoria Therapeutics Inc. filed its 10-Q for the period ending December 31, 2024. The company reported financial results and provided updates on its business -
Bionomics Limited/FI Files Q3 2024 10-Q
— Nov 14, 2024 Risk: medium
Bionomics Limited/FI filed its 10-Q for the period ending September 30, 2024. The filing details financial activities including contingent consideration in busi
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX